Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
Diseases and Conditions Researched
Idiopathic Pulmonary Fibrosis
What is the purpose of this trial?
This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.
Click here for detailed participation information for this trial.
|Sponsor:||InterMune Pharmaceuticals, Inc.|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.